IPATunity130, a pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel for PIK3CA/AKT1/PTEN-altered advanced triple-negative or hormone receptor-positive HER2-negative breast cancer, is ongoing (http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS1117). This evidence concerns the gene ERBB2 and breast cancer.